🇨🇭 $RO: FDA approved #Enspryng for thyroid eye disease, a home injection every four weeks, against eight IV infusions of 🇺🇸 $AMGN's #Tepezza.
Tepezza sold €495m in Q2, Enspryng €108m in all its uses. One of its two TED trials missed.
@midgardfinance.com